issued by the Supreme Court, and new patent reform legislation; that is, the America Invents Act passed under lobbying pressure from the high tech industry (Fig. 1) . Many of the changes did not directly target the biotech and pharma fields, yet the decisions do apply across industries. Although these changes are beneficial mostly to the high tech industry, the erosion of patent rights disproportionately harms biotech and pharma, which are dependent on strong patents due to longer investment cycles, larger capital requirements and the ease with which products can be reverse-engineered.
Higher hurdles to obtaining a patent Several court decisions have created additional and higher hurdles in satisfying the legal requirements for obtaining a patent. In 2007, after 41 years of silence on the issue, the Supreme Court revisited the criteria for what makes an invention obvious, and thus not deserving of patent protection. In KSR v. Teleflex 5 , the Court introduced "common sense" as a new and rather vague test for obviousness: the invention is obvious if common sense tells you that it is. As a result, "common sense obviousness" and "obvious to try" have become routine rejections used by patent examiners, making it harder to obtain a patent by effectively increasing the burden necessary to demonstrate nonobviousness to the examiner. KSR has also made it easier to challenge an already granted patent on obviousness grounds. Technologies that combine several established techniques or elements, as well as those that apply incremental modifications to existing inventions, are those most affected by this ruling. Because biotech, particularly drug development, often relies on patenting incremental changes, the KSR decision is a concern for many companies.
In the last two years, the Supreme Court has taken a fresh look at 35 USC Section 101, the statute governing patent eligibility for On the other hand, patenting is crucial to the success of most biopharma companies. Some drugs may be covered by one single patent. But because patent applications must be filed shortly after the discoveries are made, and well before clinical trials begin, biopharma companies file many more patents on potential drug candidates than ultimately make it to market. And owing to the high cost of maintaining patents, most initial patents are abandoned as the drug development pipeline narrows. The information found in these patents is free to the public even before the patent term expires.
Without patent protection, a biopharma company cannot effectively protect its most valuable assets-drug compositions-most of which can be easily reverse-engineered by a competitor. An exclusivity period of at least 12.9 years is required to recoup the development costs of the average biotech drug 1 . Not surprisingly, even at the initial stages of drug R&D, most investors and potential partners often turn to a company's intellectual property portfolio when determining whether or not to pursue an investment or partnership. In the biotech and pharma industries, where multibillion dollar investments are often required 2 , lack of patent protection is often a deal breaker, or at least a downward driver of valuation.
The importance of patent protection in the development of medical innovations cannot be overestimated. Of the more than 300 therapeutic agents on the World Health Organization's essential medicines list, only three are currently covered by a patent 3 but the large majority had been the subject matter of a patent application at some point 4 . This finding suggests that the patent system plays a role in improving people's health worldwide. Without patent protection, these essential medical innovations might have never reached patients.
Over the past decade, there has been a substantial weakening of patent rights on two fronts: a barrage of unfavorable patent decisions I n the last decade, the US Supreme Court and the US Congress have been diligently chipping away at the foundation of the US patent system. Court decisions and legislative acts-many of which are not directly related to medical innovations-have nevertheless had an unintended and disproportionately negative impact on the biotech and pharma industries. The unprecedented weakening of patent rights in the United States undermines necessary incentives for the discovery and development of much-needed innovative medicines, and will soon start having an impact on patients with diseases and conditions that are not amenable to current treatments.
A patent provides an inventor with the right to exclude others from using the patented invention for a limited period of time, in exchange for full disclosure of the invention. Others are free to learn from and improve upon the invention during the exclusivity period-usually 20 years from the application date-but upon the patent's expiration the invention becomes freely available to anyone. Thus, a patent can enrich the inventor for a limited time, but society is enriched with the knowledge forever. However, not all industries benefit equally from the patent system. The high tech industry, for example, relies on a multitude of technologies-and hundreds or thousands of patents-combined into a single product, be it an airplane or an iPhone, which is a logistical nightmare for companies. At the same time, patents afford little to no advantage to established companies, as these businesses primarily rely on superior operational advantages (think Apple, Facebook or Twitter) to keep competitive copycats in check.
Court rulings. The guidelines will affect many applications currently pending at the USPTO, particularly those with subject matter pertaining to the life sciences and chemistry, as patent examiners must now scrutinize all applications that touch upon, even arguably, a 'judicial exception' (i.e., an abstract idea, a law of nature or a natural principle, a natural phenomenon or a natural product). Not only have Prometheus and Myriad uprooted the established patent law framework for determining what is and what is not eligible for patent protection, these decisions also made the US the only jurisdiction in the world that excludes from patent eligibility whole classes of biomedical inventions that are patentable elsewhere in the world.
Higher hurdles in patent enforcement
In addition to increasing the hurdles for obtaining a patent, recent legal decisions and legislation have also made it harder to enforce a patent against a potential infringer. This weakening of patent enforcement rights leads to reduced leverage for patent holders licensing patents or trying to stop patent infringement. In eBay v. MercExchange 10 , the Supreme Court overturned decades of established law when it no longer allowed the granting of automatic permanent injunctions against infringers. Instead, the Court decided that an injunction should be issued only after a federal court employs a four-factor test. Without the automatic permanent injunction, the likelihood of a preliminary injunction at the outset of the litigation is greatly reduced. As a result, an infringer can make a business calculation to sell infringing products before litigating the merits of the case. Thus, the eBay decision opened the door for so-called "at risk" launches of competing pharmaceutical products, mostly generics, allowing competing products to enter the market and compete with brand-name Supreme Court in a unanimous decision overturned more than 30 years of established patent practice by eliminating isolated sequences from patent eligibility. "Groundbreaking, innovative, or even brilliant discovery does not by itself satisfy the Section 101 inquiry, " wrote Justice Clarence Thomas in the Court's opinion. According to the Court, Myriad was merely trying to protect "natural phenomena. " In fact, Myriad's patent claims were not directed at gene sequences per se, but rather at the sequences in their isolated form. Claims such as, 'an isolated XYZ substance' , have long been accepted as a valid approach for claiming purified or isolated substances extracted from nature (e.g., insulin, antibiotics, blood coagulation factors). The Court of Appeals for the Federal Circuit had twice previously considered these types of claims, upholding them on both occasions. Nevertheless, the Supreme Court held that for genomic sequences, the act of isolation does not go far enough in distinguishing them from genomic DNA. As a result, the Court made it harder for biotech companies to secure market exclusivity for fundamental discoveries. The Court did hold, however, that synthetically created genetic material, such as complementary DNA (cDNA), is patent-eligible because it is not naturally occurring. In sum, where a single sequence claim may have previously been sufficient to secure broad patent protection, multiple and diverse narrower claims will now be necessary to restore the commercially relevant competitive playing field to pre-Myriad levels, thereby considerably increasing the resources required to obtain patent protection of important discoveries.
Following the Supreme Court's lead, in March 2014, the US Patent and Trademark Office (USPTO) issued controversial guidelines for examiners that expanded the interpretation of the Prometheus and Myriad cases to limits beyond those envisioned by the Supreme inventions. The Court's decisions effectively upended the well-established, broad understanding that "anything under the sun that is made by man" is eligible for patent protection 6 . In Prometheus v. Mayo 7 , for example, the Court was asked to determine the patentability of method-of-treatment claims that involved correlating the effectiveness of the treatment with the amount of a drug metabolite in the blood. The Court reasoned that the claims were attempting to cover a "law of nature" (i.e., the correlation itself), which is not "man-made" and therefore not patent-eligible under Section 101. The Court determined that steps of "administering" the drug and "determining" the amount of the metabolite in the blood, that is, the steps that are performed by man, did not "add enough to their statements of the correlations to allow the processes they describe to qualify as patent-eligible. " In Alice v. CLS Bank 8 , the Court considered whether patent claims to a computer-implemented method of mitigating risk in financial transactions were merely an "abstract idea" not eligible for patenting. Similar to its earlier rationale advanced in Prometheus, the Court concluded that the claims amounted to nothing "significantly more" than an instruction to apply the abstract idea using an "unspecified, generic computer. " Exactly what constitutes "enough" or "significantly more" based on the Court's standards is unclear, even to most experienced patent attorneys. It remains to be seen how the courts will apply the 'enoughness' standard to future cases. But it is certain that these cases will have a major impact on personalized medicine and diagnostic technologies, as they fundamentally rely on various 'natural' correlations similar to those found in Prometheus.
Another recent case focusing on Section 101 that made headlines is Association for Molecular Pathology v. Myriad Genetics 9 . Here, the 
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F e s t o v . S h o k e t s u M e r c k v . I n t e g r a e B a y v . M e r c E x c h a n g e M e d I m m u n e v . G e n e n t e c h K S R v . T e le e x B io lo g ic s P r ic e C o m p e t it io n a n d I n n o v a t io n A c t R a t e s T e c h n o lo g y v . S p e a k e a s y paT e n T S 19 , in which the Court held that the burden of proving infringement rests with the patent holder, even when it is the licensee who initiates the suit seeking declaratory judgment that a particular product does not infringe the underlying licensed patent.
It should be noted that not all Supreme Court rulings have gone against patent holders. In one of the most serious attacks on the patent system, Microsoft asked the Supreme Court in Microsoft v. i4i 20 to eliminate the long-accepted presumption of validity for an issued patent. This presumption dictates that a patent validity challenger, such as Microsoft in this case, must prove in court by clear and convincing evidence, rather than merely by a preponderance of evidence, that the granted patent was issued in error. Typically unsympathetic to patents, the Supreme Court surprisingly sided with i4i in affirming the presumption of patent validity.
Although Microsoft lost the fight at the Supreme Court, the America Invents Act of 2011 (AIA) may have provided it with its desired outcome. Among the numerous changes to the patent system, the law introduced European-like oppositions and litigation-like proceedings at the USPTO. Unlike in the courts, these USPTO proceedings allow third parties to challenge the validity of a patent at the USPTO with no presumption of validity attached. The dust from this piece of legislation has not yet settled, but we are already hearing voices on Capitol Hill, and from President Obama himself, calling for 'Patent Reform 2.0, ' which has strong support from the high tech industry.
Finally, manufacturers of brand-name biologic products may face competition from generic manufacturers sooner as a result of the Biologics Price Competition and Innovation Act of 2009 (Biosimilars Act), signed into law in 2010 as part of the Affordable Care Act. Similar to the 1984 Hatch-Waxman Act for small molecules, the Biosimilars Act established a truncated pathway by which the FDA could approve generic versions of biologics. Under this law, new biologics are granted 12 years of regulatory exclusivity, irrespective of patent status; however, after this period generic biologics can enter the market. Moreover, a competitor can obtain 12 years of new market In a decision rendered the same day as Limelight, the Supreme Court made it easier for patent infringers to invalidate a patent claim. The Patent Act requires inventors to describe their inventions in "full, clear, concise, and exact terms" 14 . Failing to meet this requirement invalidates the patent claim. However, previously, courts would invalidate a claim only if it was "insolubly ambiguous, " meaning some "amendable construction" or reasonable interpretation could not be assigned to it. This long-established high bar for invalidation was removed by the Supreme Court in Nautilus v. Biosig Instruments 15 . In its place, the Court held that a patent could be invalidated if the patent fails to convey with "reasonable certainty" the scope of the invention. This new standard introduces a lower bar and greater ambiguity about how a court will rule, considerably raising the risk to patent holders.
Lower hurdles in challenging a patent Finally, recent decisions and legislation make it easier for patents to be challenged after they have been issued. These cases represent a loss for patent holders who find their patents an easier target for competitors. In Festo v. Shoketsu Kinzoku Kogyo Kabushiki 16 , the Supreme Court held that the two-centuryold doctrine of equivalents (DOE) should not be used if the relevant patent claim has been narrowed during the prosecution of the patent. DOE is intended to deter design-arounds that inadvertently escape the literal language of a patent claim. As almost all biotech and pharma patents are amended at some point during prosecution, Festo has essentially eviscerated the doctrine, paving the way for trivial design-arounds. This seemingly technical case, decided in 2002, marked the beginning of an onslaught of Supreme Court rulings on patent cases, almost invariably deciding against patent holders.
In a further diminution of patent rights, the Supreme Court held in MedImmune v. Genentech 17 that a patent licensee does not have to breach or terminate the license agreement before bringing an action challenging the scope or validity of a licensed patent. The licensee, accordingly, can challenge the patent while at the same time still reaping the benefits afforded by the license. The Court's decision in MedImmune represents a loss for patent holders who are now forced to take additional precautions before entering into license agreements.
Even if patent holders take certain precautions, they are now limited in their ability to do so. Following MedImmune, the rights of patent holders were even further eroded when the Supreme Court refused to review the US products for precious market share while at the same time fighting the brand-name product in a patent infringement suit.
The struggle between brand-name drugs trying to maintain market dominance and generic drugs trying to enter the market is not limited to the eBay decision. Whereas the 1984 Hatch-Waxman Act offered a safe harbor permitting generic manufacturers to 'infringe' a patent for the purposes of obtaining approval for a generic drug by means of an abbreviated new drug application (ANDA), there always remained the question about what particular activities were exempted. In 2005, in Merck KGaA v. Integra 11 , the Supreme Court enlarged the exemption to any activity "reasonably related" to most other drug applications, such as investigational new drugs, new drug applications and biologic license applications. In the more recent case Momenta v. Amphastar 12 , the Federal Circuit was asked to determine whether post-approval activities qualified for the safe harbor protection under the HatchWaxman Act. In that case, Momenta, a generic manufacturer of the drug enoxaparin, owned a patent directed to methods for analyzing heterogeneous populations of sulfated polysaccharides in enoxaparin. Amphastar, another generic manufacturer, infringed this patent by using the claimed method for quality control batch testing during its manufacture of generic enoxaparin. In its decision, the Federal Circuit sided with Amphastar and expanded the scope of the safe harbor to cover even post-approval testing, as long as the testing included information that may need to be submitted to the US Food and Drug Administration (FDA).
In Limelight v. Akamai 13 , the Supreme Court frustrated the ability of patent holders to demonstrate infringement by third parties. Limelight was accused of induced infringement for performing some steps of a method patented by Akamai and inducing others to carry out the remaining steps. While the Federal Circuit held that liability for inducement can be found even when not all the steps are performed by a single entity, the Supreme Court reversed the decision, ruling that the acts of direct infringement must be attributable to a single actor. The decision provides an avenue to evade inducement liability by dividing the method steps with third parties (e.g., the diagnostic step is performed by one entity and the treatment step by another). As personalized medicines often consist of screening a patient for a biomarker and then administering a therapy based the results, if the two steps are performed by two independent entities, infringement liability can thus be avoided in view of Limelight.
paT e n T S npg number of patients, we need a patent system where scientific disclosure is encouraged, intellectual property rights are temporary (rather than permanent trade secrets) and returns on investments are sufficient to incentivize costly drug development.
By weakening the patent system, we reduce incentives for innovators to publicly disclose their inventions and inhibit the discovery and development of innovative medicines. Doing so harms not only those who invent new therapeutics, but also generations of patients in dire need of breakthrough treatments. A wiser long-term approach is to err on the side of encouraging disclosure, not promoting trade secrecy.
as a way to extend the market exclusivity of their existing products rather than develop new products. Although the goal of regulatory exclusivity was to provide incentives for drug manufacturers to develop new types of drugs that may not otherwise be developed owing to economic considerations, regulatory exclusivity has instead been exploited to reward the use of existing drugs to gain the benefits of the incentive. By using their existing drugs, companies can maximize their profits while minimizing the expense of developing new drugs. The result is that fewer new drugs are becoming available. One study found that between 2005 and 2009, the FDA approved an average of 22.6 new chemical entities and biologics a year, a 37.2% reduction from 1995 to 1999 (ref. 21 ). If companies turn to market exclusivity to protect their assets in lieu of patent protection, patients may ultimately be harmed because fewer treatment options will exist.
The erosion of the patent system will ultimately have an impact on patients' access to new medical treatments. Much of the public's perception of the pharma industry has been shaped by the astronomical prices of innovative medicines made possible, in part, by government-sanctioned market exclusivity (either through patents or FDA regulations). Some may argue that fewer patents will mean lower prices for patients. For example, the day the Supreme Court decision in Myriad was announced, Ambry Genetics launched its own BRCA1/2 diagnostic test at $2,200, a 30% price cut from Myriad's test. As more competitors enter the market following the decision, the costs of the BRCA1/2 test will further decrease, allowing consumers to have access to more affordable products. However, while decreasing costs to consumers and increasing access to existing medical products may be a desirable outcome, these benefits are shortsighted as they come at the expense of future innovation. Some amount of exclusivity is necessary to compensate for the incredible costs of developing and commercializing innovative treatments. Without the reward of exclusionary rights to provide for a sufficient return on investment, companies will not invest the necessary resources into developing novel therapies. Thus, to promote innovation of new medicines and provide access to the greatest exclusivity simply by making a small change to the original brand-name product, producing a so-called 'biobetter' . With biologics having to undergo a lengthy and costly process to reach the market, biotechs may face increased pressure from competitors looking to benefit from their innovative discoveries under this legislation. Because this surrogate exclusivity is available, many fear that the incentive to file patent applications on new discoveries, and therefore to disclose inventions to the public, will be even further reduced as the industry shifts its focus to regulatory exclusivity as the most appealing option. Regulatory exclusivity comes in a variety of forms, including new chemical exclusivity, new clinical study exclusivity or supplemental exclusivity, orphan drug exclusivity or pediatric exclusivity.
Implications for patients
Much of a biotech company's worth is tied directly to its intellectual property, particularly for early-and mid-stage companies without an approved product and attendant revenue stream. The reduction of patent protection ushered in by recent court decisions and legislation could be devastating, as without sufficient patent protection, many innovative startups will struggle to attract the necessary funding. As a result, many potentially lifesaving technologies will never be developed and come to market.
Biotech and pharma companies may choose to protect their innovations through other means, such as trade secrets. Under trade secret law, a company does not have to file a special application. It simply needs to keep the invention-including manufacturing methods and complex formulations-a secret in order to avoid having to assume the risks that come with public disclosure in a legal environment providing insufficient patent protection against imitators and infringers. As scientific and technological progress fundamentally relies on public disclosure of findings, enabling scrutiny, collective discussion and third-party improvements, trade secrets stifle innovation by withholding from the public knowledge that otherwise would have been disclosed in patents.
Additionally, biotech and pharma companies may chose to rely on regulatory exclusivity paT e n T S npg
